Ladies talking


Targeted testing for hereditary breast and ovarian cancer syndromes

BRCA1 and BRCA2 mutations account for most families with hereditary breast and ovarian cancer syndrome (HBOC),1 and the estimated lifetime risk of breast cancer in women with BRCA1 mutations is 50% to 80%; for BRCA2, the risk is 40% to 70%.2


At Labcorp, we understand the importance of identifying patients with a BRCA mutation. With the analytical sensitivity and specificity of Labcorp’ BRCAssure assay, and a comprehensive suite of tests to identify BRCA mutations associated with breast and ovarian cancer, you can have confidence in the test performance and select the BRCAssure testing option that is the most appropriate for your patient based on her or his personal or family medical history.

BRCA estimated lifetime cancer risk chart

BRCA Risk Chart

Helping patients understand their results

Discussing BRCAssure testing results with patients can be a challenge in the short time you have to speak with them during an appointment. To help simplify the discussion, Integrated Genetics is pleased to provide you with patient reports for our BRCAssure Comprehensive and BRCAssure Ashkenazi Jewish tests. Each report provides information on the test result and the possible next steps, if any, the patient should consider, including speaking with a genetic counselor. 

BRCAssure Ashkenazi Jewish:

Test Options


  1. American College of Obstetricians and Gynecologists. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. Obstet Gynecol. April 2009; 113:957-66. Reaffirmed 2013.
  2. Petrucelli N, Daly MB and Feldman GL. BRCA1 and BRCA2 hereditary breast and ovarian cancer. GeneReviews. Available at: Published September 4, 1998. Updated September 26, 2013. Accessed October 22, 2013.